Literature DB >> 1600345

Endothelial heterogeneity and the acquired immunodeficiency syndrome: a paradigm for the pathogenesis of vascular disorders.

S Goerdt1, C Sorg.   

Abstract

Vascular disorders comprise a wide range of diverse disease entities. Correspondingly, vessels, and even more so the endothelial which line them, show a remarkable extent of heterogeneous differentiation, e.g. between the blood vascular and lymphatic systems, along the length of the vascular trees, and in the microvascular beds of various organs. The most important morphologic criterion to discriminate between endothelia is continuity (continuous endothelial cell layer and well-formed basement membrane) versus discontinuity (intra- or intercellular gaps and/or reduced or missing basement membrane). Most blood vascular endothelia are of the continuous type, while most sinusoidal and lymphatic endothelia are discontinuous by these criteria. Antigen expression corroborates these morphologic data in that CD31, CD34, and 1F10 antigen are exclusively expressed in continuous endothelia, while MS-1 antigen is preferentially expressed in non-continuous sinusoidal endothelia. In contrast, no specific marker has as yet been described for lymphatic endothelia. Endothelial heterogeneity substantially contributes to the pathogenesis of vascular disorders. For example, in patients with acquired immunodeficiency syndrome the same infectious agent may cause either bacillary angiomatosis (a lobular capillary proliferation) or peliosis (sinusoidal dilatation, endothelial denudation, and development of blood-filled cysts) depending on whether the affected organs have predominantly continuous endothelia or noncontinuous sinusoidal endothelia. Moreover, in Kaposi's sarcoma, it is still an open question of whether the lesion is derived from blood vascular or lymphatic endothelia (Kaposi's sarcoma cells in situ do not express the von Willebrand factor+, PAL-E+, 1F10+ phenotype of mature, resting blood vascular endothelia). It is also unresolved how endothelia of either type may be differentially induced to dedifferentiate and how they are recruited into the lesion. Clearly, knowledge about endothelial heterogeneity is still too incomplete to identify the actual mechanisms and molecules that govern the pathogenesis of vascular disorders (including still others than those mentioned here such as atherosclerosis, diabetic angiopathy, and rheumatoid arthritis) affecting distinct endothelia. Further efforts in antigenic phenotyping and in cell and molecular biology of heterogeneously differentiated endothelia should be made to improve this state of affairs.

Entities:  

Mesh:

Year:  1992        PMID: 1600345     DOI: 10.1007/bf00227347

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  110 in total

1.  Sinusoidal dilatation occurring in livers of mice with a transplanted testicular tumor.

Authors:  J T WOLSTENHOLME; W U GARDNER
Journal:  Proc Soc Exp Biol Med       Date:  1950-08

2.  Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin.

Authors:  R Cerio; C E Griffiths; K D Cooper; B J Nickoloff; J T Headington
Journal:  Br J Dermatol       Date:  1989-10       Impact factor: 9.302

3.  Peliosis hepatis. Possible etiologic role of anabolic steroids.

Authors:  F Naeim; P H Copper; A A Semion
Journal:  Arch Pathol       Date:  1973-04

4.  Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium.

Authors:  D M Knowles; B Tolidjian; C Marboe; V D'Agati; M Grimes; L Chess
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

5.  Peliosis hepatis and sinusoidal dilation during infection by the human immunodeficiency virus (HIV). An ultrastructural study.

Authors:  J Y Scoazec; C Marche; P M Girard; J Houtmann; A M Durand-Schneider; A G Saimot; J P Benhamou; G Feldmann
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

6.  In situ localization of melanotransferrin (melanoma-associated antigen P97) in human liver. A light- and electronmicroscopic immunohistochemical study.

Authors:  R Sciot; R de Vos; P van Eyken; K van der Steen; P Moerman; V J Desmet
Journal:  Liver       Date:  1989-04

Review 7.  Histogenesis of Kaposi's sarcoma and angiosarcoma of the face and the scalp.

Authors:  C A Holden
Journal:  J Invest Dermatol       Date:  1989-08       Impact factor: 8.551

8.  Peliosis: a morphologic curiosity becomes an iatrogenic problem.

Authors:  J B Taxy
Journal:  Hum Pathol       Date:  1978-05       Impact factor: 3.466

9.  NEW CYTOPLASMIC COMPONENTS IN ARTERIAL ENDOTHELIA.

Authors:  E R WEIBEL; G E PALADE
Journal:  J Cell Biol       Date:  1964-10       Impact factor: 10.539

10.  Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.

Authors:  D D Wagner; J B Olmsted; V J Marder
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

View more
  4 in total

Review 1.  Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.

Authors:  Andreas Bauwens; Josefine Betz; Iris Meisen; Björn Kemper; Helge Karch; Johannes Müthing
Journal:  Cell Mol Life Sci       Date:  2012-07-06       Impact factor: 9.261

2.  Expression of stabilin-1 in M2 macrophages in human granulomatous disease and melanocytic lesions.

Authors:  Kathrin Schönhaar; Kai Schledzewski; Julia Michel; Claudia Dollt; Cleopatra Gkaniatsou; Cyrill Géraud; Julia Kzhyshkowska; Sergij Goerdt; Astrid Schmieder
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 3.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

4.  Vascular origin of Kaposi's sarcoma. Expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor.

Authors:  Y M Zhang; S Bachmann; C Hemmer; J van Lunzen; A von Stemm; P Kern; M Dietrich; R Ziegler; R Waldherr; P P Nawroth
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.